UNLABELLED: Nicotinic acetylcholine receptors (nAChRs) play an important role in tobacco dependence and a potential therapeutic role in neuropsychiatric disorders such as Alzheimer's disease. [123I]5-iodo-3-[2(S)-2-azetidinylmethoxy]pyridine (5-I-A-85380) is a new SPECT tracer that labels alpha4beta2 nAChRs. The purpose of this study was to assess the usefulness of this tracer to measure regional nAChR binding in baboon brain using both a bolus/kinetic paradigm and also a bolus plus constant infusion/equilibrium paradigm. METHODS: A pair of bolus/kinetic and bolus plus constant infusion/equilibrium studies was performed in each of 3 isoflurane-anesthetized baboons. Bolus studies were performed by intravenous injection of 191-226 MBq [123I]5-I-A-85380 and image acquisition for 289-367 min. The data were analyzed with 1- and 2-tissue compartment models. Bolus plus constant infusion/equilibrium studies were performed by a bolus injection (74-132 MBq) followed by a 468- to 495-min infusion with a bolus/infusion ratio (B/I) of 4.8-5.0 h. The distribution volumes in the thalamus were measured in these 2 paradigms. To study whether the cerebellum was appropriate as a receptor-poor region, displacement studies were done in 2 baboons using the B/I paradigm with subcutaneous injection of (-)-cytisine (0.8 and 1.0 mg/kg). RESULTS: The kinetics of this tracer was best described by the 1-tissue compartment model. The 2-compartment model showed poor identifiability of rate constants. The total (specific plus nondisplaceable compartments) distribution volumes (V(T)') agreed between bolus and B/I paradigms (average percentage difference in V(T)', 16.8%). (-)-Cytisine (0.8 and 1.0 mg/kg) displaced 70% and 72% of the radioactivity in the thalamus and 36% and 55% in the cerebellum, respectively, indicating that the latter was not appropriate as a receptor-poor region. CONCLUSION: These results show the feasibility of quantifying alpha4beta2 nAChRs using [123I]5-I-A-85380 and support the use of V(T)' as an appropriate outcome measure.
UNLABELLED: Nicotinic acetylcholine receptors (nAChRs) play an important role in tobacco dependence and a potential therapeutic role in neuropsychiatric disorders such as Alzheimer's disease. [123I]5-iodo-3-[2(S)-2-azetidinylmethoxy]pyridine (5-I-A-85380) is a new SPECT tracer that labels alpha4beta2 nAChRs. The purpose of this study was to assess the usefulness of this tracer to measure regional nAChR binding in baboon brain using both a bolus/kinetic paradigm and also a bolus plus constant infusion/equilibrium paradigm. METHODS: A pair of bolus/kinetic and bolus plus constant infusion/equilibrium studies was performed in each of 3 isoflurane-anesthetized baboons. Bolus studies were performed by intravenous injection of 191-226 MBq [123I]5-I-A-85380 and image acquisition for 289-367 min. The data were analyzed with 1- and 2-tissue compartment models. Bolus plus constant infusion/equilibrium studies were performed by a bolus injection (74-132 MBq) followed by a 468- to 495-min infusion with a bolus/infusion ratio (B/I) of 4.8-5.0 h. The distribution volumes in the thalamus were measured in these 2 paradigms. To study whether the cerebellum was appropriate as a receptor-poor region, displacement studies were done in 2 baboons using the B/I paradigm with subcutaneous injection of (-)-cytisine (0.8 and 1.0 mg/kg). RESULTS: The kinetics of this tracer was best described by the 1-tissue compartment model. The 2-compartment model showed poor identifiability of rate constants. The total (specific plus nondisplaceable compartments) distribution volumes (V(T)') agreed between bolus and B/I paradigms (average percentage difference in V(T)', 16.8%). (-)-Cytisine (0.8 and 1.0 mg/kg) displaced 70% and 72% of the radioactivity in the thalamus and 36% and 55% in the cerebellum, respectively, indicating that the latter was not appropriate as a receptor-poor region. CONCLUSION: These results show the feasibility of quantifying alpha4beta2 nAChRs using [123I]5-I-A-85380 and support the use of V(T)' as an appropriate outcome measure.
Authors: Aybala Saricicek; Irina Esterlis; Kathleen H Maloney; Yann S Mineur; Barbara M Ruf; Anjana Muralidharan; Jason I Chen; Kelly P Cosgrove; Rebecca Kerestes; Subroto Ghose; Carol A Tamminga; Brian Pittman; Frederic Bois; Gilles Tamagnan; John Seibyl; Marina R Picciotto; Julie K Staley; Zubin Bhagwagar Journal: Am J Psychiatry Date: 2012-08 Impact factor: 18.112
Authors: Irina Esterlis; Jonas O Hannestad; Frederic Bois; R Andrew Sewell; Rachel F Tyndale; John P Seibyl; Marina R Picciotto; Marc Laruelle; Richard E Carson; Kelly P Cosgrove Journal: J Nucl Med Date: 2012-11-15 Impact factor: 10.057
Authors: Irina Esterlis; Kelly P Cosgrove; Jeffery C Batis; Frederic Bois; Stephanie M Stiklus; Evgenia Perkins; John P Seibyl; Richard E Carson; Julie K Staley Journal: J Nucl Med Date: 2010-07-21 Impact factor: 10.057
Authors: James Robert Brasić; Yun Zhou; John L Musachio; John Hilton; Hong Fan; Andrew Crabb; Christopher J Endres; Melvin J Reinhardt; Ahmet S Dogan; Mohab Alexander; Olivier Rousset; Marika A Maris; Jeffrey Galecki; Ayon Nandi; Dean F Wong Journal: Synapse Date: 2009-04 Impact factor: 2.562
Authors: Alexey G Mukhin; Alane S Kimes; Svetlana I Chefer; John A Matochik; Carlo S Contoreggi; Andrew G Horti; D Bruce Vaupel; Olga Pavlova; Elliot A Stein Journal: J Nucl Med Date: 2008-09-15 Impact factor: 10.057
Authors: Irina Esterlis; Effie M Mitsis; Jeffery C Batis; Frederic Bois; Marina R Picciotto; Stephanie M Stiklus; Tracy Kloczynski; Edward Perry; John P Seibyl; Sherry McKee; Julie K Staley; Kelly P Cosgrove Journal: Int J Neuropsychopharmacol Date: 2010-10-29 Impact factor: 5.176
Authors: Effie M Mitsis; Kelly P Cosgrove; Julie K Staley; Frederic Bois; Erin B Frohlich; Gilles D Tamagnan; Kristina M Estok; John P Seibyl; Christopher H van Dyck Journal: Neurobiol Aging Date: 2008-02-01 Impact factor: 4.673
Authors: Masahiro Fujita; Masanori Ichise; Christopher H van Dyck; Sami S Zoghbi; Gilles Tamagnan; Alexey G Mukhin; Ali Bozkurt; Nicholas Seneca; Dnyanesh Tipre; Christopher C DeNucci; Hidehiro Iida; D Bruce Vaupel; Andrew G Horti; Andrei O Koren; Alane S Kimes; Edythe D London; John P Seibyl; Ronald M Baldwin; Robert B Innis Journal: Eur J Nucl Med Mol Imaging Date: 2003-10-02 Impact factor: 9.236